Research programme: cancer therapeutics - Boehringer Ingelheim/FORMA
Latest Information Update: 13 Jan 2014
At a glance
- Originator Boehringer Ingelheim; FORMA Therapeutics
- Class Small molecules
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Jan 2014 Early research is ongoing in USA
- 05 Jan 2012 Early research in Cancer in USA (unspecified route)